Diallyl disulfide synergizes with melphalan to increase apoptosis and DNA damage through elevation of reactive oxygen species in multiple myeloma cells
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Diallyl disulfide (DADS), one of the main components of garlic, is well known to have anticancer effects on multiple cancers. However, its efficacy in treating multiple myeloma (MM) is yet to be determined. We explored the effects of DADS on MM cells and investigated the synergistic effects of DADS when combined with five anti-MM drugs, including melphalan, bortezomib, carfilzomib, doxorubicin, and lenalidomide. We analyzed cell viability, cell apoptosis, and DNA damage to determine the efficacy of DADS and the drug combinations. Our findings revealed that DADS induces apoptosis in MM cells through the mitochondria-dependent pathway and increases the levels of γ-H2AX, a DNA damage marker. Combination index (CI) measurements indicated that the combination of DADS with melphalan has a significant synergistic effect on MM cells. This was further confirmed by the increases in apoptotic cells and DNA damage in MM cells treated with the two drug combinations compared with those cells treated with a single drug alone. The synergy between DADS and melphalan was also observed in primary MM cells. Furthermore, mechanistic investigations showed that DADS decreases reduced glutathione (GSH) levels and increases reactive oxygen species (ROS) production in MM cells. The addition of GSH is effective in neutralizing DADS cytotoxicity and inhibiting the synergy between DADS and melphalan in MM cells. Taken together, our study highlights the effectiveness of DADS in treating MM cells and the promising therapeutic potential of combining DADS and melphalan for MM treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Annals of hematology - 103(2024), 4 vom: 01. März, Seite 1293-1303 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00277-023-05592-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366389971 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366389971 | ||
| 003 | DE-627 | ||
| 005 | 20240327235552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-023-05592-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM366389971 | ||
| 035 | |a (NLM)38148345 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diallyl disulfide synergizes with melphalan to increase apoptosis and DNA damage through elevation of reactive oxygen species in multiple myeloma cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Diallyl disulfide (DADS), one of the main components of garlic, is well known to have anticancer effects on multiple cancers. However, its efficacy in treating multiple myeloma (MM) is yet to be determined. We explored the effects of DADS on MM cells and investigated the synergistic effects of DADS when combined with five anti-MM drugs, including melphalan, bortezomib, carfilzomib, doxorubicin, and lenalidomide. We analyzed cell viability, cell apoptosis, and DNA damage to determine the efficacy of DADS and the drug combinations. Our findings revealed that DADS induces apoptosis in MM cells through the mitochondria-dependent pathway and increases the levels of γ-H2AX, a DNA damage marker. Combination index (CI) measurements indicated that the combination of DADS with melphalan has a significant synergistic effect on MM cells. This was further confirmed by the increases in apoptotic cells and DNA damage in MM cells treated with the two drug combinations compared with those cells treated with a single drug alone. The synergy between DADS and melphalan was also observed in primary MM cells. Furthermore, mechanistic investigations showed that DADS decreases reduced glutathione (GSH) levels and increases reactive oxygen species (ROS) production in MM cells. The addition of GSH is effective in neutralizing DADS cytotoxicity and inhibiting the synergy between DADS and melphalan in MM cells. Taken together, our study highlights the effectiveness of DADS in treating MM cells and the promising therapeutic potential of combining DADS and melphalan for MM treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a DNA damage | |
| 650 | 4 | |a Diallyl disulfide | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Melphalan |2 NLM | |
| 650 | 7 | |a Q41OR9510P |2 NLM | |
| 650 | 7 | |a diallyl disulfide |2 NLM | |
| 650 | 7 | |a 5HI47O6OA7 |2 NLM | |
| 650 | 7 | |a amsonic acid |2 NLM | |
| 650 | 7 | |a 81-11-8 |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Allyl Compounds |2 NLM | |
| 650 | 7 | |a Disulfides |2 NLM | |
| 650 | 7 | |a 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid |2 NLM | |
| 650 | 7 | |a 27816-59-7 |2 NLM | |
| 700 | 1 | |a Sun, Jingqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a He, Fen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Weihong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhijian |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Jiaqi |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Zhanyou |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jiarui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiayu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Junjun |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Jiliang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g 103(2024), 4 vom: 01. März, Seite 1293-1303 |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:1293-1303 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-023-05592-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 4 |b 01 |c 03 |h 1293-1303 | ||